Form 4: CRISPR Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, sold 1,040 shares of common stock on October 13, 2026 for $49.26 per share.
Summary
- Option exercise/conversion: acquired 2,113 Common Shares on October 13, 2026; holds 96,897 after (Direct).
- Open-market sale: disposed of 1,040 Common Shares at $49.26 ($51,230) on October 14, 2026; holds 95,857 after (Direct).
- Option exercise/conversion: disposed of 2,113 Restricted Stock Units on October 13, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $51,230 of stock on the open market.
Insider Transactions
James R. Kasinger — Officer (General Counsel and Secretary)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-13 | Option exercise/conversion | Common Shares | 2,113 | — | — | 96,897 |
| 2026-10-14 | Open-market sale | Common Shares | 1,040 | $49 | $51.2K | 95,857 |
| 2026-10-13 | Option exercise/conversion | Restricted Stock Units | 2,113 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-13 | Option exercise/conversion (2,113 shares) |
| 2026-10-14 | Open-market sale (1,040 shares) |
| 2026-10-13 | Option exercise/conversion (2,113 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, James R. Kasinger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.